From 1987 to 1999 35 patients with poor prognosis non-Hodgkin's lymphoma (NHL) underwent allogeneic stem cell transplantation (SCT) at the University Hospitals of Vienna and Graz. Initial biopsy specimens were reclassified according to the Revised European-American Classification of Lymphoid Neoplasms (REAL). All patients surviving 28 days engrafted. Twenty-eight of them (93%) attained clinical remission. At the last follow-up 14 patients were alive and disease-free at a median of 5.0 (range, 2.3-12.9) years after allogeneic SCT. The actuarial overall survival is 35%. Five patients relapsed 1.8 to 27.6 months after transplant, the probability of relapse is 23%. Of the 21 deaths following SCT, seven were due to relapse/refractory disease and 14 due to transplant-related causes. The probability of treatment-related mortality is 48%. After SCT, minimal residual disease (MRD) was monitored by polymerase chain reaction (PCR) in seven patients with a BCL-2/IgH translocation and in 13 with a clonal immunoglobulin heavy chain (IgH) rearrangement. All 20 patients attained clinical remission rapidly and converted to PCR negativity. In the follow-up nine of these patients are in long-term clinical and molecular remission, six PCR-negative patients died of transplant-related causes and five patients relapsed. In summary, allogeneic stem cell transplantation has a curative potential for patients with refractory and recurrent non-Hodgkin's lymphoma. In our series long-term disease-free survival was associated with molecular disease eradication after SCT. Treatmentrelated mortality rate was high, thus earlier referral of selected patients to allogeneic SCT should be considered. Leukemia (2001) 15, 635-641.
Introduction
Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of malignant diseases with increasing incidence. 1 The intensive research of the last decades has improved our knowledge of molecular pathogenesis of the different lymphoma subgroups. 2 Numerous clinical trials have been undertaken to improve the treatment outcome, but still only 40-50% of patients with aggressive NHL can be cured by conventional chemotherapy. Incorporation of consolidating highdose chemotherapy with autologous stem cell support into first-line therapy can improve the results in aggressive NHL with high or high-intermediate risk. 3, 4 In patients with chemotherapy-sensitive relapsed aggressive NHL autologous SCT has become the treatment of choice, but only a few patients with chemotherapy-resistant or primary refractory NHL can benefit from autologous SCT. [5] [6] [7] In indolent lymphoma the situation is more controversial. 8, 9 Because of the relatively long natural history of these diseases, the problem of tumor contamination of the stem cell harvest and the high risk of post-transplant secondary myelodysplastic syndrome, autologous SCT should be restricted to selected patients. 10, 11 The primary cause of treatment failure after autologous SCT in NHL is relapse, at least partially due to re-infusion of tumor cells.
Allogeneic SCT offers the advantage of tumor-free stem cells and a possible graft-versus-lymphoma effect, but is associated with a much higher toxicity and depends on the availability of a histocompatible donor. Non-randomized studies demonstrated a reduction of relapse by approximately half compared to autologous transplantation, but this advantage was upset by the high treatment-related mortality. [12] [13] [14] [15] Nevertheless, some patients with poor prognosis NHL attain long-term clinical remissions. [16] [17] [18] [19] [20] As other hematologic malignances NHLs are characterized by non-random genetic alterations. A clonal IgH rearrangement can be detected in the majority of patients with NHL and about 90% of follicular lymphomas and some diffuse large B cell lymphomas are characterized by the t(14;18). 21, 22 These clonal markers provide a useful tool for sensitive monitoring of minimal residual disease (MRD) by polymerase chain reaction (PCR).
Our study presents the clinical results of allogeneic SCT in patients with poor prognosis NHL at two university hospitals. We determined the frequency of clonal immunoglobulin heavy chain (IgH) rearrangements and the BCL-2/IgH translocations in pre-transplant samples of NHL patients by PCR. Minimal residual disease (MRD) was monitored after allogeneic SCT in order to determine the clinical value of molecular monitoring in NHL.
Patients and methods

Patients
Between March 1987 and September 1999 35 patients with non-Hodgkin's lymphoma (NHL) underwent allogeneic stem cell transplantation at the University Hospitals of Vienna and Graz. Patient and transplant characteristics are shown in Table  1 . Initial biopsy specimens were reclassified according to the Revised European-American Classification of Lymphoid Neoplasms (REAL). In our small series the majority had follicular lymphoma, diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma (71%). In addition, also one patient with chronic lymphocytic leukemia, mantle cell lymphoma and small lymphocytic lymphoma were included. All patients presented with poor prognostic features based on persistent or recurrent disease after front-line therapy. Ageadjusted IPI at diagnosis was two or higher in 27 patients (77%). Thirty patients (86%) had stage III or IV disease at diag- nosis as shown in Table 1 . Patients underwent SCT after one to five (median three) different chemotherapy regimens and 23 (66%) were in progressive disease at SCT. The latter group was heterogeneous including patients with primary refractory lymphomas and lymphomas in second or subsequent relapse. Histocompatibility studies were performed as previously described. 23 Stem cell donors were HLA-identical siblings. Bone marrow was harvested and infused as described. 24 The total number of nucleated stem cells infused ranged from 0. )/kg of recipient body weight. Protocols for graft-versus-host disease prophylaxis are shown in Table 1 . 25, 26 The clinical diagnosis of GVHD was confirmed by appropriate biopsies and clinically graded as 0 to IV by the criteria reported for acute GVHD and as none, limited, or extensive for chronic GVHD. 27, 28 Patients were hospitalized in isolation rooms with laminar air-flow or reverse isolation. They received antimicrobial prophylaxis with nonabsorbable antibiotics, Pneumocystis carinii and cytomegalovirus (CMV) prophylaxis. 29 Packed red blood cells (RBC) were given to maintain hemoglobin concentrations above 8.0 g/dl and platelet transfusions to keep platelet counts above 20 × 10 9 /l. All patients received CMV-negative blood products. All but one patient treated after 1990 received G-CSF until recovery of granulopoesis. Informed consent was obtained from all patients. Data were analyzed as of 29 February 2000.
Documentation of hematopoietic engraftment
All patients had peripheral blood (PB) and reticulocyte counts on a daily basis starting 7 days before SCT until hematopoietic engraftment. Differential counting was carried out from smears after modified Wright staining, absolute neutrophil counts (ANC) were calculated from leukocyte and differential counts. The time required for marrow engraftment was defined by the first day on which the absolute granulocyte count reached 0.5 × 10 9 /l for 3 consecutive days. Bone marrow (BM) aspirates were performed on days 30, 100 and 365 after transplantation. Engraftment of donor cells was also documented by cytogenetic analyses of recipient marrow cells before and after transplantation and amplification of highly variable DNA regions (short tandem repeats, STR) of different sex-independent genes by polymerase chain reaction (PCR). [30] [31] [32] [33] [34] Amplification of the variable number of tandem repeats (VNTR) of the von Willebrand factor gene, the factor XIII B gene and the APOC2 gene were performed as previously described. [31] [32] [33] [34] For amplification of the tyrosine hydroxylase gene and the thyroid peroxidase gene, a commercially available kit was used (Promega, Madison, WI, USA).
Statistical methods
Overall survival, probability of relapse, and treatment-related mortality were determined by the Kaplan-Meier method. 35 
Isolation of DNA
DNA was prepared from BM and PB mononuclear cells using cell lysis, proteinase K digestion (Boehringer Mannheim, Mannheim, Germany), phenol extraction, and ethanol precipitation according to standard procedures. 36 
PCR analysis of rearranged immunoglobulin heavy chain genes
PCR amplification of the complementary determining region 3 (CDR 3) of the immunoglobulin heavy chain (IgH) gene was performed with four different pairs of oligonucleotide primers as previously described. 21 The sensitivity of the IgH PCR systems was determined by dilution of DNA of monoclonal cells from a patient at the time of diagnosis with DNA from polyclonal mononuclear cells of healthy individuals. The sensitivity of the IgH PCR was 0.1% to 1% in repeated assays. 21 
PCR analysis of the BCL-2/IgH translocation
PCR amplification of the BCL-2/IgH translocation involving the major breakpoint region (MBR) was performed with nested primers as described. 37 Samples collected before 1997 were analyzed retrospectively. The sensitivity of this two-step PCR was determined by dilution of DNA of the cell line RL7 with DNA from polyclonal mononuclear cells of healthy individuals. The sensitivity was 0.001% in repeated assays.
Results
Engraftment
Five patients (14%) died within 4 weeks of stem cell grafting and thus, could not be evaluated for engraftment; all others successfully engrafted. The median time to reach more than 0.5 × 10 9 /l ANC was 16 (range, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] 
Clinical outcome
Five patients died within 1 month after allogeneic SCT and their remission status could not be ascertained. Twenty-eight of 30 evaluable patients (93%) attained clinical remission, including eight who had been transplanted in CR or PR. Two patients died of disease progression between 0.8 and 2.1 months after SCT. As of February 2000, 14 patients (40%) are alive and disease-free at a median of 5 (range, 2.3-12.9) years post-transplant. The probability of overall survival (OS) projected at 5 years after allogeneic SCT as determined by the Kaplan-Meier method is 35% (Figure 1a) , consisting of 53% for patients transplanted in CR and 26% for those with progressive disease at SCT. Progression (n = 2)/relapse (n = 5) accounted for seven deaths between 0.8 and 45 months after SCT. In six of these patients, disease status at SCT was PD. The probability of relapse at 5 years is 23% (Figure 1b) . It is 17% for patients transplanted in CR and 25% for those with progressive disease at SCT. Seven patients died of early, another seven of late transplant-related complications as summarized in Table 2 . The Kaplan-Meier analysis revealed a probability of TRM projected at 5 years of 48%. No statistically significant difference for probability of OS, relapse and TRM was observed between patients transplanted in CR or in progressive disease.
GVHD
Excluding the early deaths, 23 of 30 evaluable patients (77%) developed acute GVHD including 20 with grades I-II and four with grades III-IV. Eight of 26 patients (31%) surviving longer than 100 days developed chronic GVHD, seven had preceding acute GVHD. Three patients developed limited chronic GVHD and five extensive chronic GVHD, including two with still ongoing GVHD. There was no correlation between probability of GVHD and relapse. No., number; TRM, transplant-related mortality; GVHD, graftversus-host disease.
Leukemia
Monitoring of MRD after allogeneic SCT and correlation with clinical results
MRD was monitored in seven BCL-2/IgH positive patients (Figure 2a ). All attained molecular remission 0.5 to 6 months after SCT. Patients 1 to 3 are in long-term molecular and clinical remission, whereas patients 4 and 6 died of transplant- Although the two PCR assays had at least a 100-fold difference in sensitivity, the results were comparable, as documented in patient No. 5. PCR negativity or positivity of both the BCL-2/IgH translocation and the IgH rearrangement was essentially the same in PB and BM samples when analyzed at the same time-points.
Discussion
The role of allogeneic SCT in the treatment of patients with NHL is controversial and randomized trials comparing allogeneic with autologous SCT have not been performed. However, several non-randomized, comparative studies have been published demonstrating for the allogeneic group a reduced risk of relapse by approximately half compared with autolog-ous transplantation, but an increased treatment-related mortality.
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We report long-term results in 35 patients with poor prognosis NHL who received allogeneic SCT. The majority had progressive disease at SCT, was extensively pretreated and had an age adjusted IPI of 2 and above. Complete remissions were obtained in a high proportion of these patients. After a median follow-up of 5 (range, 2-13) years 14 patients (40%) are alive and disease-free, the actuarial overall survival is 35%. Although there was a trend towards improved overall survival in patients undergoing allogeneic SCT in CR or PR compared to the ones transplanted in progressive disease, no statistically significant difference was observed in our series. 40 Considering the fact that a substantial number of patients with refractory lymphoma attained long-term disease-free survival, our results compare favorably with other published data of allogeneic SCT in poor prognosis NHL. 38 Similar to previous reports, transplant-related morbidity and mortality were the main reasons negatively impairing our results. 19, 39, 40, 41 The probability of TRM projected at 5 years was 48%. Thus, the results of allogeneic SCT could be improved by investigating dose-reduced conditioning regimens. 42 In addition, referral of patients earlier in the course of their disease could allow further improvement of long-term results since TRM was reportedly higher in patients who had received more pretransplant therapy. 38 Since the majority of our patients was heavily pretreated, the impact of previous therapy on TRM could not be evaluated in our series.
In our study, only five patients developed relapse, four of them had high-grade lymphoma. Eradication of lymphoma cells by immune-mediated graft-versus-lymphoma (GVL) effect is the major advantage of allogeneic SCT compared with autologous SCT. 13 Khouri et al 43 demonstrated a GVL effect in patients with mantle cell lymphoma by the achievement of remission concomitant with GVHD and conversion from positive PCR status early after transplantation to negative status over time. Discontinuation of immunosuppressive therapy or donor lymphocyte infusions (DLI) can induce remissions in the case of disease recurrence. Bernard et al 16 gave DLI to two relapsing patients with low-grade lymphoma and both developed GVHD. One patient with FL re-entered CR and is still in CR after 24 months, in the other case a partial, transient remission was observed. Furthermore, Mandigers et al 19 documented a CR after DLI given to two patients with relapse of FL and developing only limited chronic GVHD thereafter. In Van Besien's study four of nine patients in relapse responded to withdrawal of immunosuppression (two CR, two PR), but no response to DLI was observed in another three patients including two with diffuse large cell lymphoma and one with prolymphocytic lymphoma. 44 Molecular monitoring of clonal markers has been used by several groups to assess patients' risk to relapse and to identify lymphoma patients in need for post-transplant therapy. [45] [46] [47] Apostolidis et al 45 reported that in patients with follicular lymphoma only four of 23 patients (17%) with consistently BCL-2/IgH negative samples relapsed after autologous SCT, whereas 12 of 13 patients (92%) with positive PCR results developed recurrent lymphoma. Compared to autologous SCT monitoring of MRD in lymphoma patients was less frequently reported after allogeneic SCT. Juckett et al 18 found BCL-2/IgHpositivity in six of eight patients (75%) after allogeneic T celldepleted BMT. Whereas two of these relapsed, the others remained progression-free after a median follow-up of 5 years. Our results concerning the BCL-2/IgH translocation are in contrast to these results since all our patients attained molecuLeukemia lar remission 0.5 to 6 months after SCT. Rapid molecular disease eradication was achieved in three patients with highgrade and four with low-grade lymphoma. The sensitivity of our PCR assay is comparable to the one used by Juckett et al. T cell depletion of BM prior to SCT could potentially explain the discrepancy in PCR results. Whether the prolonged PCR positivity reported by Juckett et al indicates persistence of lymphoma cells and is of clinical relevance, has to remain unanswered. Since relapse rates are known to be substantially higher after T cell-depleted SCT, relapses could still be observed in these PCR-positive patients after longer observation times. Khouri et al 43 applied PCR to monitor BCL-1 or immunoglobulin gene rearrangements in seven patients with mantle cell lymphoma. Five of these patients converted to PCR negativity. Another patient with mantle cell lymphoma who achieved PCR negativity of the IgH rearrangement after allogeneic SCT was reported by Corradini et al. 48 Masuda et al 49 described the disappearance of the BCL-2 rearrangement in a patient with refractory follicular lymphoma after allogeneic SCT.
In our study, all patients with a BCL-2/IgH translocation and/or a IgH rearrangement attained both molecular and clinical remission. Although the two-step BCL-2/IgH PCR and the one-step PCR for the IgH rearrangement had at least a 100-fold difference in sensitivity, the PCR results obtained correlated well. Both persistent PCR negativity of the BCL-2/IgH translocation and the IgH rearrangement were associated with long-term clinical remission. Due to the low relapse number seen in our series, further studies with larger patient numbers are necessary to clarify the predictive value of molecular monitoring after allogeneic SCT. In conclusion, allogeneic SCT offers cure in a substantial proportion of patients with poor risk NHL. In our study, serial PCR analyses of the BCL-2 translocation and the IgH rearrangement documented that long-term clinical remission in these patients is associated with molecular disease eradication. The preliminary results of our small study, however, have to be confirmed with larger patient numbers.
In the future, dose-reduced conditioning regimens used for allogeneic nonmyeloablative SCT and adoptive immunotherapy post transplant could allow a reduction in TRM and thus, provide more benefit to patients with poor risk NHL than autologous SCT. During these treatment regimens molecular monitoring might help to find the optimal time-point and dose for immunomodulatory therapy to achieve final disease eradication.
